<DOC>
	<DOC>NCT01993875</DOC>
	<brief_summary>To evaluate the pharmacodynamics and tolerability of a liquid formulation of lubiprostone, as compared to matching placebo, when administered orally to subjects with chronic idiopathic constipation. Additionally, liquid formulation pharmacokinetics, including a comparison of fed and fasted pharmacokinetics, of the liquid formulation will be performed in a subset of subjects.</brief_summary>
	<brief_title>Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Lubiprostone</mesh_term>
	<criteria>Medicallyconfirmed diagnosis of chronic idiopathic constipation Willing to discontinue use of prescribed or overthecounter (OTC) medication that affects gastrointestinal motility during the study Stable dose of selective serotonin reuptake inhibitors (SSRIs), serotoninspecific reuptake inhibitor (SNRIs), or monoamine oxidase inhibitors (MAO) inhibitors Any gastrointestinal (GI) condition, other than constipation, affecting GI motility or defecation. Medical/surgical condition that might interfere with the absorption, distribution, metabolism, or excretion of the study medication.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>